Sentences with phrase «zoledronic acid»

«In summary, we found that a single infusion of zoledronic acid in frail, cognitively challenged, less mobile elderly women improved bone density and reduced bone turnover for two years.

Treatment with zoledronic acid was associated with an eight percent increase in lumbar spine bone marrow density at 12 weeks relative to the placebo arm, with an 11 percent increase at 24 and 48 weeks.

A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long - term - care facilities, according to an article published online by JAMA Internal Medicine.

The denosumab and zoledronic acid groups were statistically similar in all areas but spine bone mineral density (increased 0.060 g / cm2 versus 0.021 g / cm2, respectively) and flulike symptoms (none versus 29 percent of patients).

In a related commentary, Robert Lindsay, M.B., Ch.B., Ph.D., of Helen Hayes Hospital, West Haverstraw, N.Y., writes: «In this issue of JAMA Internal Medicine, Greenspan and colleague present intriguing data on zoledronic acid, one of the most potent drugs in the bisphosphonate family — if not the most potent — approved for treatment of osteoporosis.»

Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway.

Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S - and M - phase cyclins and p21CIP1expression.

«The indication is that zoledronic acid exerts a benefit through a variety of mechanisms which, all together, create a tumor - hostile environment...»

-- the issued patent contains only 2 claims directed at zoledronic acid and therefore patent is sufficient

In the mouse study, a single injection of zoledronic acid was able to prevent bone loss without impairing the rebuilding of the immune system.

Treatment with zoledronic acid was associated with a 73 percent and a 65 percent reduction in bone loss relative to placebo at 12 weeks and 24 weeks respectively, an effect that lasted throughout the 48 weeks of the study.

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV - infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).

The researchers assessed 343 individuals for eligibility, and 63 were selected and randomized to receive either ART and placebo, or ART and zoledronic acid.

Zoledronic acid was approved by the FDA in 2007 for osteoporosis.

Zoledronic acid was chosen because it can be given in a single intravenous dose and the effect can last for two years.

«Bone mineral density improved in frail elderly women treated with zoledronic acid.»

Of the women, 89 were assigned to receive a single 5 - mg dose of zoledronic acid and 92 were assigned to receive placebo, while all participants received daily vitamin D and calcium supplementation.

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms.

Researchers performed a retrospective chart review and survey of 107 patients to compare the efficacy, patient satisfaction, cost and known adverse effects of denosumab versus zoledronic acid, including muscle pain, back pain and flulike symptoms.

Susan L. Greenspan, M.D., of the University of Pittsburgh, and coauthors conducted a clinical trial to determine the efficacy and safety of zoledronic acid to treat osteoporosis in frail elderly women living in long - term care facilities.

The Austrian researchers also found that women who took Zometa (zoledronic acid) had a 30 percent lower risk of the cancer spreading to the bone, with other benefits as well.